UGT1A1 and colorectal cancer: For Italian colorectal cancer patients, the estimated costs were 6-fold greater for the UGT1A1*28/*28 genotype (4,886 euros) than the wild-type genotype UGT1A1*1/*1 (812 euros); for heterozygous patients with the *1/*28 genotype, the estimated costs were 1,119 euros, still significantly higher than for the wild-type patients.